Overview of Dr. Bello
Dr. Celeste Bello is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from University of South Florida Morsani College of Medicine and has been in practice 15 years. Dr. Bello accepts several types of health insurance, listed below. She is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. She has more than 30 publications and over 500 citings.
Office
12901 USF Magnolia Dr
Tampa, FL 33612Fax+1 727-462-7904
Education & Training
- University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2006 - 2009
- University of South Florida MorsaniResidency, Internal Medicine, 2002 - 2005
- University of South Florida College of MedicineClass of 2002
Certifications & Licensure
- FL State Medical License 2005 - 2025
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Start of enrollment: 2010 Mar 01
- Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia Start of enrollment: 2011 Apr 06
- Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL Start of enrollment: 2012 Mar 30
- Join now to see all
Publications & Presentations
PubMed
- 214 citationsBrentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expressionEric D. Jacobsen, Jeff P. Sharman, Yasuhiro Oki, Ranjana H. Advani, Jane N. Winter
Blood. 2015-02-26 - 46 citationsOutcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data.Rami S. Komrokji, Najla Al Ali, Muhammad Shaalan Beg, M. M. Safa, Dana E. Rollison
Clinical Lymphoma, Myeloma & Leukemia. 2011-06-01 - 486 citationsIdelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.Jennifer R. Brown, John C. Byrd, Steven Coutre, Don M. Benson, Ian W. Flinn
Blood. 2014-05-29
Abstracts/Posters
- Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment FailureCeleste Bello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-RCeleste Bello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt ExperienceCeleste Bello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Anthem HealthKeepers HMO/POS
Anthem KeyCare PPO
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CareFirst BCBS Maryland POS
CareFirst BlueChoice AdvantageCareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: